A total of 7 studies were included in the DCR of RET fusion-positive NSCLC patients treated with RET-TKIs, and the heterogeneity of these 7 studies of literature was not statistically significant (I2 < 50%, P > 0.1). This evidence concerns the gene RET and non-small cell lung carcinoma.